AbbVie Inc. (ABBV)

AbbVie Revenue by Segment

Period Ending	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Immunology	26.34B	26.08B	25.92B	26.14B	27.11B	27.98B	28.37B	28.92B
Immunology Growth	-2.83%	-6.78%	-8.64%	-9.64%	-2.30%	4.51%	10.47%	14.40%
Neuroscience	8.58B	8.26B	7.99B	7.72B	7.33B	6.96B	6.74B	6.53B
Neuroscience Growth	17.06%	18.70%	18.59%	18.21%	13.30%	9.36%	9.21%	10.14%
Hematologic Oncology	6.37B	6.20B	6.04B	5.92B	6.04B	6.18B	6.35B	6.58B
Hematologic Oncology Growth	5.57%	0.37%	-4.81%	-10.07%	-11.47%	-12.22%	-11.86%	-9.01%
Aesthetics	5.25B	5.25B	5.24B	5.29B	5.21B	5.27B	5.26B	5.33B
Aesthetics Growth	0.75%	-0.44%	-0.30%	-0.73%	-4.46%	-2.42%	-3.79%	1.91%
Other Products	3.70B	3.79B	3.78B	3.81B	3.82B	3.85B	3.88B	3.85B
Other Products Growth	-3.14%	-1.51%	-2.50%	-1.25%	-11.01%	-17.57%	-23.74%	-29.79%
Eye Care	2.18B	2.26B	2.35B	2.42B	2.42B	2.44B	2.54B	2.70B
Eye Care Growth	-9.88%	-7.26%	-7.60%	-10.59%	-21.20%	-26.54%	-27.92%	-24.28%

Revenue by Geography

Period Ending	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
US	42.11B	41.72B	41.88B	42.97B	43.88B	44.57B	45.71B
US Growth	-4.03%	-6.38%	-8.38%	-4.94%	-1.87%	0.96%	5.16%
International	12.89B	12.68B	12.44B	12.17B	12.15B	12.18B	12.34B
International Growth	6.12%	4.15%	0.76%	-3.55%	-3.86%	-3.50%	-2.73%

Operating Expense Breakdown

Period Ending	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018
Selling, General, and Administrative	14.09B	13.26B	13.15B	12.87B	13.10B	13.03B	15.17B	15.26B
Selling, General, and Administrative Growth	7.59%	1.76%	-13.34%	-15.65%	-13.29%	-12.46%	20.09%	23.57%
Research and Development	7.94B	7.54B	7.32B	7.68B	7.54B	7.43B	7.31B	6.51B
Research and Development Growth	5.39%	1.45%	0.23%	17.90%	15.14%	12.66%	8.19%	-5.95%
Acquired In-Process R&D	1.47B	1.45B	792.00M	778.00M	739.00M	713.00M	702.00M	697.00M
Acquired In-Process R&D Growth	98.24%	103.23%	12.82%	11.62%	-13.97%	-41.61%	-35.24%	-37.99%
Other Expenses	-	-	-	-	-	49.00M	46.00M	56.00M
Other Expenses Growth	-	-	-	-	-	-85.06%	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.